AstraZeneca's Form 6-K reveals Koselugo's EU approval for inoperable plexiform neurofibromas, based on promising KOMET trial results. A significant step for NF1 patients.
Discover AstraZeneca PLC's latest Form 6-K detailing voting rights and share capital as of August 31, 2025. Key info for shareholders on compliance and transparency.
Explore AstraZeneca's latest report on anselamimab's Phase III trial for AL amyloidosis, highlighting key findings and future steps.
Discover AstraZeneca's total voting rights and regulatory compliance in the July 2025 report, vital for shareholders and investor relations.
Discover AstraZeneca's June 2025 Block Listing Interim Review, detailing securities management and share option plans. Key insights on compliance and financial performance.
Explore key insights from AstraZeneca's 2025 AGM, highlighting shareholder support, board changes, and future outlook. Discover why we recommend a 'Hold' amid market uncertainties.
Explore BioMarin's 2024 financial report showcasing revenue growth, strategic R&D investments, and a strong buy recommendation. Key insights reveal a promising outlook for investors.
Explore Fulcrum Therapeutics' 2024 financial report detailing revenue growth, reduced losses, and a strong liquidity position. Key insights on collaboration and profitability challenges.
AstraZeneca's Form 6-K details the CALYPSO trial results for eneboparatide, indicating significant potential for treating chronic hypoparathyroidism. Key findings and next steps outlined.
Explore Travere Therapeutics' Q4 2024 Financial Report highlighting $233M in revenue and increased net losses. Insights and hold recommendation for investors.
Explore GeneDx Holdings Corp's Q4 2024 financial insights, revealing impressive revenue growth, improved net loss, and ongoing challenges in operational efficiency and legal matters.
Discover key insights from Amicus Therapeutics' 2024 10-K Report, detailing revenue growth, financial health, and investment strategies. Current stock recommendation: Hold.